checkAd

    EQS-News  125  0 Kommentare Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 - Seite 3

    Contact
    Heidelberg Pharma AG
    Sylvia Wimmer
    Director Corporate Communications
    Tel.: +49 89 41 31 38-29
    E-Mail: investors@hdpharma.com
    Gregor-Mendel-Str. 22, 68526 Ladenburg
     
    IR/PR-Support
    MC Services AG
    Katja Arnold (CIRO)
    Managing Director & Partner
    Tel.: +49 89 210 228-40
    E-Mail: katja.arnold@mc-services.eu
     
    International IR/PR-Support
    Optimum Strategic Communications
    Mary Clark, Zoe Bolt, Katie Flint
    Tel: +44 20 3882 9621
    E-Mail: HeidelbergPharma@optimumcomms.com
     

    This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.



    27.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: Heidelberg Pharma AG
    Gregor-Mendel-Str. 22
    68526 Ladenburg
    Germany
    Phone: +49 (0)89 41 31 38 - 0
    Fax: +49 (0)89 41 31 38 - 99
    E-mail: investors@hdpharma.com
    Internet: www.heidelberg-pharma.com
    ISIN: DE000A11QVV0
    WKN: A11QVV
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1868185
    Seite 3 von 4



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 - Seite 3 EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 27.03.2024 / 09:01 CET/CEST The issuer is solely responsible for the content of this …